Genenta Science S.p.A.
NASDAQ: GNTA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pierluigi Paracchi
- Employees
- 13
- Headquarters
- Milan, Italy
- IPO year
- 2021
- Market cap
- $35.4M
- Website
- https://www.genenta.com
Loading GNTA…
Loading profile data…Frequently asked questions about GNTA
What does Genenta Science S.p.A. (GNTA) do?
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically...
Where does GNTA trade?
Genenta Science S.p.A. (GNTA) trades on the NASDAQ Capital Market.
What sector is GNTA in?
Genenta Science S.p.A. (GNTA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Genenta Science S.p.A.?
Pierluigi Paracchi is the chief executive officer of Genenta Science S.p.A. (GNTA).
Where is Genenta Science S.p.A. headquartered?
Genenta Science S.p.A. is headquartered in Italy.
Does GNTA pay a dividend?
Genenta Science S.p.A. (GNTA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GNTA go public?
Genenta Science S.p.A. (GNTA) completed its initial public offering in 2021.
Is GNTA an ADR?
Yes — GNTA is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Genenta Science S.p.A. reporting and dividends follow the underlying issuer.